Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812679 · ClinicalTrials.gov registry record · NA
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
A NA study, sponsored by Vantive Health.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT03812679 is a NA study that was terminated before completion, run by Vantive Health. The registered enrollment target is 22 participants.
The verdict
NCT03812679, a NA study, was terminated before completion, sponsored by Vantive Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD). Complementary therapies offer longer term survival for patients with ESRD. However, none of them are devoid of side effects and today their limitations are better understood by the nephrologist. The AMIA APD Solution Generation System combines an updated AMIA APD Cycler with Sharesource Platform (previously cleared) with an in-home water system technology and leverages newly developed AMIA APD Concentrates. The AMIA APD Concentrates, after dilution by the AMIA APD Solution Generation System, are indicated for adult patients in acute or chronic renal failure when non-dialytic medical therapy is judged to be inadequate.
Interventions
- DEVICE AMIA APD Solution Generation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2020-02-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03812679
The ClinicalTrials.gov registry entry for NCT03812679 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMIA APD Solution Generation System is the first listed.
NCT03812679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03812679 about?
NCT03812679 is a clinical study titled "Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)". Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD). Complementary therapies offer longer term survival for patients with ESRD....
What is the current status of trial NCT03812679?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2018-12-20. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03812679?
The interventions under investigation include: AMIA APD Solution Generation System (DEVICE).
Who is sponsoring clinical trial NCT03812679?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.